North America Tumor Ablation Market Report and Forecast 2024-2032

North America Tumor Ablation Market Report and Forecast 2024-2032

North America Tumor Ablation Market Report and Forecast 2024-2032

North America Tumor Ablation Market Outlook

The North America tumor ablation market size was valued at USD 0.71 billion in 2023, driven by the rising prevalence and incidence of cancer in the region. The market is expected to grow at a CAGR of 12.30% during the forecast period of 2024-2032, with the values likely to rise from USD 0.79 billion in 2024 to USD 2.01 billion by 2032.

Key Takeaways

• In March 2024 , Medtronic plc announced FDA 501 (k) clearance for its bone tumor ablation system called OsteoCool 2.0 to treat benign bone tumors and painful bone metastases.
• The American Cancer Society estimated around 2,001,140 new cancer cases and 611,720 deaths caused by cancer in the United States in 2024.
• In September 2023 , the United States Food and Drug Administration (FDA) approved ablation treatment planning and confirmation software, VisAble.IO, to facilitate image-guided ablation therapy.

North America Tumor Ablation Market Analysis

Tumor ablation is a minimally invasive technique in which interventional radiologists guide a needle-tipped catheter directly into a tumor, followed by applying extreme heat or cold to destroy or shrink the tumor. Imaging techniques are generally used to precisely find the tumor location. The ability of tumor ablation treatment to shrink tumors can increase the longevity of patients, relieve pain, and even in some cases, cure cancer. The technical success of the treatment and its minimally invasive nature is expected to drive the North America tumor ablation market demand in the coming years.

Cancer ranks as the second leading cause of mortality in the United States. American Cancer Society estimated around 2,001,140 new cancer cases and 611,720 deaths are projected to affect the United States population in 2024. The rising cancer burden directly impacts the demand for effective treatment approaches to tackle the mortality rate caused by the disease. Thus, the growing prevalence of cancer is expected to positively influence the North America tumor ablation market share in the region.

The market is witnessing a surge in approvals from health regulatory authorities such as the United States Food and Drug Administration (FDA). In March 2024 , United States based Medtronic plc announced FDA 501 (k) clearance for its bone tumor ablation system called OsteoCool 2.0. The upgraded design of the radiofrequency ablation system allows efficient treatment of benign bone tumors and painful bone metastases. The device can use four internally cooled probes at the same time and delivers 20W per channel, with the company claiming it as the most powerful bone tumor ablation on the market. Further, the company plans to introduce the product in the United States market this year. The launch of such innovative ablation systems is likely to augment the North America tumor ablation market growth in the forecast period.

The market is witnessing technological innovation in the field of tumor ablation systems which are increasing treatment precision and improving patient outcomes. In September 2023 , the United States Food and Drug Administration (FDA) granted approval to ablation treatment planning and confirmation software, VisAble.IO, developed by Techsomed, an Israeli-based medical device company. The software uses the company’s artificial intelligence-driven technology called BioTrace and facilitates image-guided ablation therapy, offering various advantages such as three-dimensional visualization of the ablation target. The rising integration of artificial intelligence in tumor ablation treatment is expected to optimize patient care and fuel market growth.

Other factors that drive the market share include the rising investment from the public and private sectors, heightened public awareness regarding the benefits of the technique, and the expanding applications of tumor ablation systems.

North America Tumor Ablation Market Segmentation  

“North America Tumor Ablation Market Report and Forecast 2024-2032” offers a detailed analysis of the market based on the following segments:

Market Breakup by Technology

• Radiofrequency (RF)Ablation
• Microwave Ablation
• Cryoablation
• Irreversible Electroporation
• Others

Market Breakup by Mode of Treatment

• Surgical Ablation
• Laparoscopic Ablation
• Percutaneous Ablation
• Others

Market Breakup by Application

• Liver Cancer
• Lung Cancer
• Kidney Cancer
• Bone Metastasis
• Others

Market Breakup by End User

• Hospital and Clinics
• Specialty Centers
• Others

Market Breakup by Countries

• United States of America
• Canada

North America Tumor Ablation Market: Competitor Landscape

The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Sonacare Medical
• Medtronic Plc
• EDAP TMS
• Angiodynamics
• Healthtronics, INC
• Johnson & Johnson
• Boston Scientific Corporation
• Misonix, INC
• Biotronik

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

FAQs

• What was the North America tumor ablation market value in 2023?

The market attained a value of about USD 0.71 billion in 2023 driven by the rising prevalence and incidence of cancer in the region.

• What is the North America tumor ablation market forecast outlook for 2024-2032?

The market is anticipated to grow at a CAGR of 12.30% during the forecast period of 2024-2032, likely to reach a market value of USD 2.01 billion by 2032.

• What are the major factors aiding the North America tumor ablation market demand?

Technological innovations in tumor ablation systems and the rising preference for minimally invasive techniques are fuelling the demand for the market.

• What are the major North America tumor ablation market trends?

One of the significant trends in the market is the surge in approvals from health regulatory authorities such as the United States FDA. In March 2024 , Medtronic plc announced 501 (k) clearance for its bone tumor ablation system called OsteoCool 2.0. The upgraded design of the radiofrequency ablation system allows efficient treatment of benign bone tumors and painful bone metastases.

• What is the market segmentation based on technology?

Based on the technology, the market is segmented into radiofrequency (RF) ablation, microwave ablation, cryoablation, and irreversible electroporation, among others.

• What is the market breakup by mode of treatment?

By mode of treatment, the market is divided into surgical ablation, laparoscopic ablation, and percutaneous ablation, among others.

• What are the major end users of tumor ablation market in North America?

End users of the market are hospitals, clinics, and specialty centers, among others.

• What are the applications of North America tumor ablation market?

Major application areas of tumor ablation include liver cancer, lung cancer, kidney cancer, and bone metastasis, among others.

• What is the market segmentation by countries?

The market segmentation by countries includes the United States of America and Canada.

• Who are the key players involved in the North America tumor ablation market?

The key players in the market are Sonacare Medical, Medtronic Plc, EDAP TMS, Angiodynamics, Healthtronics, INC, Johnson & Johnson, Boston Scientific Corporation, Misonix, INC, and Biotronik.

Meta description

The North America tumor ablation market size was valued at USD 0.71 billion in 2023 and it is anticipated to grow at a CAGR of 12.30% during the forecast period of 2024-2032.

*Please Note:* The report will take 7 business days to complete, after order confirmation.